Post-vaccine adverse events in patients immunized against COVID-19 in a munici-pality in the south of Santa Catarina state in 2021
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2023.203651Keywords:
Coronavirus infection, Vaccination, Drug-related side effects and adverse reactionsAbstract
The mass availability of vaccines against the SARS-CoV-2 virus is the result of worldwide scientific efforts. However, insecurity and popular hesitation permeate the antivaccine movements. Objective: Analyze the profile of Post-Vaccine Adverse Events (PVAE) in the city of Tubarão, SC, Brazil, in 2021. Methodology: Cross-sectional epidemiological
study with data from all standard PVAE notification forms in the city of Tubarão-SC in 2021. The variables analyzed were the epidemiological profile of the patient, the immunobiological administered, the type of event and the evolution of the cases. The incidence rate (IR) was calculated for 10,000 doses ap-plied. Results: The study population was 274 patients, 73% were female, with a mean age of 39.8±14.5 years. A total of 197,001 doses were applied in the year 2021, resulting in an overall IR of 13.9. There were 206 reactions reported in pa-tients immunized with
AstraZeneca (IR=29.1), 43 with Pfizer (IR=5.1), 18 with Coro-navac (IR=4.8) and seven with Janssen (IR=13.8).
There were only seven cases classified as severe (IR=0.3) and, of these, one patient died, with no causal rela-tionship established. Conclusion: The overall incidence of serious events was low, which corroborates the safety profile of available immunobiologicals against COVID-19.
Downloads
References
Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. Hirst JA, organizador. PLoS ONE. 6 de abril de 2021;16(4):e0249788.
Chua PEY, Shah SU, Gui H, Koh J, Somani J, Pang J. Epidemiological and clin-ical characteristics of non-severe and severe pediatric and adult COVID-19 pa-tients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies. J Investig Med. 16 de junho de 2021;jim-2021-001858.
Ministério da Saúde. Painel de casos de doença pelo coronavírus 2019 (COVID-19) no Brasil pelo Ministério da Saúde [Internet]. 2021. Disponível em: https://covid.saude.gov.br/
Mari J de J, Oquendo MA. Mental health consequences of COVID-19: the next global pandemic. Trends Psychiatry Psychother. setembro de 2020;42(3):219–20.
Hochman G. Vacinação, varíola e uma cultura da imunização no Brasil. Ciênc saúde coletiva. fevereiro de 2011;16(2):375–86.
Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 Vaccination Hesitancy in the United States: A Rapid National As-sessment. J Community Health. abril de 2021;46(2):270–7.
Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. BMJ. 20 de maio de 2021;n1138.
Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Imu-nizações e Doenças Transmissíveis. Manual de vigilância epidemiológica de eventos adversos pós-vacinação - 4aedição [Internet]. 2020. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_epidemiologica_eventos_vacinacao_4ed.pdf
Freeman D, Loe BS, Yu LM, Freeman J, Chadwick A, Vaccari C, et al. Effects of different types of written vaccination information on COVID-19 vaccine hesitan-cy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. The Lancet Public Health. maio de 2021;S2468266721000967.
Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Ind J Clin Biochem [Internet]. 27 de março de 2021 [citado 19 de maio de 2021]; Dis-ponível em: http://link.springer.com/10.1007/s12291-021-00968-z
Galhardi CP, Freire NP, Fagundes MCM, Minayo MC de S, Cunha ICKO. Fake News and vaccine hesitancy in the COVID-19 pandemic in Brazil. Ciênc saúde coletiva. maio de 2022;27(5):1849–58.
Freitas MBA de, Oliveira M de S, Maciel IME. ADESÃO À VACINA CONTRA A COVID 19 PELA COMUNIDADE ACADÊMICA DO UNIFUNEC. Unifunec Ci Saúde e Biol. 15 de junho de 2021;4(7):1–14.
Moore DCBC, Nehab MF, Camacho KG, Reis AT, Junqueira-Marinho M de F, Abramov DM, et al. Low COVID-19 vaccine hesitancy in Brazil. Vaccine. outubro de 2021;39(42):6262–8.
Nery N, Ticona JPA, Cardoso CW, Prates APPB, Vieira HCA, Salvador de Al-meida A, et al. COVID-19 vaccine hesitancy and associated factors according to sex: A population-based survey in Salvador, Brazil. Kumar S, organizador. PLoS ONE. 21 de janeiro de 2022;17(1):e0262649.
Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lan-cet. março de 2022;399(10328):924–44.
Sato APS. Qual a importância da hesitação vacinal na queda das coberturas vacinais no Brasil? :9.
Vaccine refusal – what we need to know. :8.
Padamsee TJ, Bond RM, Dixon GN, Hovick SR, Na K, Nisbet EC, et al. Changes in COVID-19 Vaccine Hesitancy Among Black and White Individuals in the US. JAMA Netw Open. 21 de janeiro de 2022;5(1):e2144470.
MONITORAMENTO DOS EVENTOS ADVERSOS PÓS-VACINAÇÃO (EAPV) CONTRA A COVID-19 EM SANTA CATARINA [Internet]. 2022. Disponível em: https://www.dive.sc.gov.br/phocadownload/doencas-agravos/COVID%2019/boletim-EAPV-2022-2.pdf
Ministério da Saúde. BOLETIM EPIDEMIOLÓGICO ESPECIAL - Doença pelo Novo Coronavírus – COVID-19 [Internet]. 2021. Disponível em: https://www.gov.br/saude/pt-br
Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Anal-ysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 22 de dezembro de 2021;4(12):e2140364.
Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and Gender Disparities in Ad-verse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management. Front Med. 19 de julho de 2021;8:700014.
Torjesen I. Covid-19: Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds. BMJ. 27 de maio de 2021;n1372.
Silva RB da, Silva TPR da, Sato APS, Lana FCF, Gusmão JD, Souza JFA, et al. Eventos adversos pós-vacinação contra o SARS-CoV-2 (covid-19) no estado de Minas Gerais. Rev saúde pública. 22 de outubro de 2021;55:66.
Fundação Oswaldo Cruz. Observatório Covid-19 [Internet]. 2021. Disponível em: https://portal.fiocruz.br/observatorio-covid-19
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From De-cember 2020 to August 2021. JAMA. 25 de janeiro de 2022;327(4):331.
Moro PL, Olson CK, Clark E, Marquez P, Strid P, Ellington S, et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), De-cember 2020 – October 2021. Vaccine. maio de 2022;40(24):3389–94.
Menegali BT, Schuelter-Trevisol F, Barbosa AN, Izidoro TM, Feurschuette OHM, Marcon CEM, et al. Vertical transmission of maternal COVID-19 antibodies after CoronaVac vaccine: A case report. Rev Soc Bras Med Trop. 2021;54:e0385-2021.
Ssentongo P, Ssentongo AE, Voleti N, Groff D, Sun A, Ba DM, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis. dezembro de 2022;22(1):439.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Henrique Guimarães Aires e Silva, Beatriz Ranson Margotti , Chaiana Esmeraldino Mendes Marcon
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Funding data
-
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Grant numbers R$4800
